HTG EdgeSeq Technology Highlighted in Several Posters at ASCO
“We are thrilled to see our technology highlighted in so many abstracts at this year’s ASCO conference,” said
Posters presented at the 2020 Virtual ASCO conference using HTG EdgeSeq technology include:
- Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens;
- Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma;
- Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC);
- Integrated-omics of MRI-visible and -invisible prostate cancer identifies molecular correlations with clinical outcome;
- Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS): A
Spanish Group for Research on Sarcomas(GEIS) translational study.
“The number of posters highlighting our technology at this year’s ASCO conference is a testament to the utility of our technology,” said
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential impacts on our business of these publications. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including but not limited to, risks relating to the ability of molecular subtyping to perform as intended or expected. These and other factors are described in greater detail in our filings with the
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.